» Articles » PMID: 33046544

Chemogenetic Manipulation of Dopamine Neurons Dictates Cocaine Potency at Distal Dopamine Transporters

Overview
Journal J Neurosci
Specialty Neurology
Date 2020 Oct 13
PMID 33046544
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

The reinforcing efficacy of cocaine is largely determined by its capacity to inhibit the dopamine transporter (DAT), and emerging evidence suggests that differences in cocaine potency are linked to several symptoms of cocaine use disorder. Despite this evidence, the neural processes that govern cocaine potency remain unclear. In male rats, we used chemogenetics with intra-VTA microinfusions of the agonist clozapine-n-oxide to bidirectionally modulate dopamine neurons. Using fast scan cyclic voltammetry, pharmacological probes of the DAT, biochemical assessments of DAT membrane availability and phosphorylation, and cocaine self-administration, we tested the effects of chemogenetic manipulations on cocaine potency at distal DATs in the nucleus accumbens as well as the behavioral economics of cocaine self-administration. We discovered that chemogenetic manipulation of dopamine neurons produced rapid, bidirectional modulation of cocaine potency at DATs in the nucleus accumbens. We then provided evidence that changes in cocaine potency are associated with alterations in DAT affinity for cocaine and demonstrated that this change in affinity coincides with DAT conformation biases and changes in DAT phosphorylation state. Finally, we showed that chemogenetic manipulation of dopamine neurons alters cocaine consumption in a manner consistent with changes in cocaine potency at distal DATs. Based on the spatial and temporal constraints inherent to our experimental design, we posit that changes in cocaine potency are driven by alterations in dopamine neuron activity. When considered together, these observations provide a novel mechanism through which GPCRs regulate cocaine's pharmacological and behavioral effects. Differences in the pharmacological effects of cocaine are believed to influence the development and progression of cocaine use disorder. However, the biological and physiological processes that determine sensitivity to cocaine remain unclear. In this work, we use a combination of chemogenetics, fast scan cyclic voltammetry, pharmacology, biochemistry, and cocaine self-administration with economic demand analysis to demonstrate a novel mechanism by which cocaine potency is determined These studies identify a novel process by which the pharmacodynamics of cocaine are derived , and thus this work has widespread implications for understanding the mechanisms that regulate cocaine consumption across stages of addiction.

Citing Articles

EAAT2 Activation Regulates Glutamate Excitotoxicity and Reduces Impulsivity in a Rodent Model of Parkinson's Disease.

Das S, McCloskey K, Nepal B, Kortagere S Mol Neurobiol. 2024; .

PMID: 39630405 DOI: 10.1007/s12035-024-04644-0.


Modern Methods for Unraveling Cell- and Circuit-Level Mechanisms of Neurophysiological Biomarkers in Psychiatry.

Rader Groves A, Gallimore C, Hamm J Adv Neurobiol. 2024; 40:157-188.

PMID: 39562445 DOI: 10.1007/978-3-031-69491-2_7.


Inactivation of ERK1/2 Signaling in Dopaminergic Neurons by Map Kinase Phosphatase MKP3 Regulates Dopamine Signaling and Motivation for Cocaine.

Bernstein D, Lewandowski S, Besada C, Place D, Espana R, Mortensen O J Neurosci. 2024; 44(5).

PMID: 38296649 PMC: 10860627. DOI: 10.1523/JNEUROSCI.0727-23.2023.


Hypocretin / Orexin Receptor 1 Knockdown in GABA or Dopamine Neurons in the Ventral Tegmental Area Differentially Impact Mesolimbic Dopamine and Motivation for Cocaine.

Black E, Samels S, Xu W, Barson J, Bass C, Kortagere S Addict Neurosci. 2023; 7.

PMID: 37854172 PMC: 10583964. DOI: 10.1016/j.addicn.2023.100104.


A head-to-head comparison of two DREADD agonists for suppressing operant behavior in rats via VTA dopamine neuron inhibition.

Lawson K, Ruiz C, Mahler S Psychopharmacology (Berl). 2023; 240(10):2101-2110.

PMID: 37530882 PMC: 10794001. DOI: 10.1007/s00213-023-06429-0.


References
1.
Berke J, Hyman S . Addiction, dopamine, and the molecular mechanisms of memory. Neuron. 2000; 25(3):515-32. DOI: 10.1016/s0896-6273(00)81056-9. View

2.
Calipari E, Juarez B, Morel C, Walker D, Cahill M, Ribeiro E . Dopaminergic dynamics underlying sex-specific cocaine reward. Nat Commun. 2017; 8:13877. PMC: 5234081. DOI: 10.1038/ncomms13877. View

3.
Sonders M, Zhu S, Zahniser N, Kavanaugh M, Amara S . Multiple ionic conductances of the human dopamine transporter: the actions of dopamine and psychostimulants. J Neurosci. 1997; 17(3):960-74. PMC: 6573182. View

4.
Zou M, Cao J, Abramyan A, Kopajtic T, Zanettini C, Guthrie D . Structure-Activity Relationship Studies on a Series of 3α-[Bis(4-fluorophenyl)methoxy]tropanes and 3α-[Bis(4-fluorophenyl)methylamino]tropanes As Novel Atypical Dopamine Transporter (DAT) Inhibitors for the Treatment of Cocaine Use Disorders. J Med Chem. 2017; 60(24):10172-10187. PMC: 5746459. DOI: 10.1021/acs.jmedchem.7b01454. View

5.
Desai R, Kopajtic T, Koffarnus M, Newman A, Katz J . Identification of a dopamine transporter ligand that blocks the stimulant effects of cocaine. J Neurosci. 2005; 25(8):1889-93. PMC: 6726049. DOI: 10.1523/JNEUROSCI.4778-04.2005. View